MAXCYTE, INC.
A cell-engineering company with a platform for developing cell-based therapeutics.
MXCT | US
Overview
Corporate Details
- ISIN(s):
- US57777K1060 (+2 more)
- LEI:
- 54930053YHXULRFCU991
- Country:
- United States of America
- Address:
- 9713 KEY WEST AVENUE,, 20850 ROCKVILLE
- Website:
- https://www.maxcyte.com/
Description
MaxCyte, Inc. is a cell-engineering company that provides enabling platform technologies to advance the discovery, development, and commercialization of cell-based therapeutics. Its core offering is the ExPERT™ platform, which utilizes proprietary Flow Electroporation® technology for efficient, scalable, and non-viral transfection of complex cells. This technology supports a wide range of applications, including cell therapy, gene editing, antibody and protein production, and vaccine development. Additionally, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate the safety of gene-edited products by detecting on- and off-target effects. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2018-10-31 17:25 |
Result of AGM
|
English | 15.4 KB | ||
| 2018-10-31 17:25 |
Result of AGM
|
English | 15.4 KB | ||
| 2018-10-10 09:00 |
Dosing Begins in First Clinical Trial of MCY-M11
|
English | 20.6 KB | ||
| 2018-10-10 09:00 |
Dosing Begins in First Clinical Trial of MCY-M11
|
English | 20.6 KB | ||
| 2018-10-08 09:00 |
Notice of AGM
|
English | 15.5 KB | ||
| 2018-10-08 09:00 |
Notice of AGM
|
English | 15.5 KB | ||
| 2018-09-24 09:00 |
Results for the Half Year ended 30 June 2018
|
English | 218.0 KB | ||
| 2018-09-24 09:00 |
Results for the Half Year ended 30 June 2018
|
English | 218.0 KB | ||
| 2018-09-10 09:00 |
Grant of Options
|
English | 30.5 KB | ||
| 2018-09-10 09:00 |
Grant of Options
|
English | 30.5 KB | ||
| 2018-09-03 09:00 |
Notice of Half Year Results
|
English | 15.9 KB | ||
| 2018-09-03 09:00 |
Notice of Half Year Results
|
English | 15.9 KB | ||
| 2018-07-26 19:33 |
Director/PDMR Shareholding
|
English | 25.4 KB | ||
| 2018-07-26 19:33 |
Director/PDMR Shareholding
|
English | 25.4 KB | ||
| 2018-07-16 09:00 |
FDA IND Clearance for First Clinical Programme
|
English | 19.2 KB |
Automate Your Workflow. Get a real-time feed of all MAXCYTE, INC. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for MAXCYTE, INC.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for MAXCYTE, INC. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
